Leiden thrombosis therapy spinout VarmX had raised an undisclosed seed sum in June 2017 and converted debt to equity in its latest round.
VarmX, a Netherlands-based haemostasis and thrombosis therapy spinout from Leiden University, closed a €7.5m ($8.7m) series A round yesterday that included InnovationQuarter, the provincial development agency for South Holland.
Venture capital firm BioGeneration Ventures led the round, which complemented a $5.8m loan from government-owned Netherlands Enterprise Agency’s Innovation Credit program.
Leiden University and provincial proof-of-concept fund Uniiq converted existing loans to VarmX into equity as part of the round.
Spun out in 2016, VarmX is aiming to help patients at…
